Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

25.08
-0.2700-1.07%
Pre-market: 25.180.1000+0.40%05:23 EDT
Volume:2.16M
Turnover:54.13M
Market Cap:3.14B
PE:116.43
High:25.67
Open:25.49
Low:24.73
Close:25.35
52wk High:31.77
52wk Low:15.10
Shares:125.07M
Float Shares:111.18M
Volume Ratio:1.19
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:14.22
PE(LYR):-197.70

Loading ...

Arcutis Q2 Net Income Turns to USD 15 Million; Revenue Rises 59% Year over Year to USD 129.9 Million

Reuters
·
Aug 06

Arcutis Biotherapeutics: Raised Net Product Sales Guidance for the Full Year 2026 from $480 Million–$495 Million to $525 Million–$540 Million

THOMSON REUTERS
·
Aug 06

Arcutis Biotherapeutics Q2 Operating Expenses USD 113.432 Million

THOMSON REUTERS
·
Aug 06

Arcutis Biotherapeutics Inc Expected to Post Earnings of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: Arcutis Biotherapeutics Inc. this quarter’s revenue is expected to increase by 61.29%, and institutional views are mostly bullish

Earnings Agent
·
Jul 29

Arcutis Biotherapeutics Director Christopher Peetz Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Arcutis Biotherapeutics Director Howard G. Welgus Disposes of 4,730 Common Shares Worth $127,269.30

Reuters
·
Jul 18

Arcutis Appoints Mirum CEO Chris Peetz to Board

Reuters
·
Jul 16

Arcutis Expands Board of Directors with Appointment of Chris Peetz

THOMSON REUTERS
·
Jul 16

Arcutis Biotherapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 16

Attovia Therapeutics Appoints John W. Smither to Board of Directors

THOMSON REUTERS
·
Jul 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 15

MBX Biosciences Names Steve Hoerter CEO, Replacing Kent Hawryluk

Reuters
·
Jul 14

Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies

TIPRANKS
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Seres Therapeutics (MCRB)

TIPRANKS
·
Jul 09

Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema

MT Newswires Live
·
Jul 08

Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA

TIPRANKS
·
Jul 08

FDA Accepts Arcutis Snda for Zoryve Cream Use in Infants with Atopic Dermatitis

Reuters
·
Jul 08

Arcutis Biotherapeutics - FDA Sets Pdufa Target Action Date of February 23, 2027 for Zoryve Cream 0.05% Snda

THOMSON REUTERS
·
Jul 08

FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

THOMSON REUTERS
·
Jul 08